Ii-key/HER-2/neu hybrid cancer vaccine
Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2/neu protein. The construct may be in the form of an Ii-Key hybrid peptide or a nucleic acid encoding an Ii-Key hybrid peptide. Methods are described wherein the cancer being treated is breast cancer. Also claimed is a pharmaceutical composition comprising an Ii-Key/MHC class II hybrid construct with and without an adjuvant. The adjuvant can include GM-CSF. The Ii-Key hybrid construct includes the LRMK (SEQ ID NO: 2) residues of Ii-Key protein and an MHC Class II epitope of a protein or portion thereof which is used in the vaccine or a DNA encoding the same hybrid peptide.
1. A method of preventing or reducing recurrence of a cancer in a disease-free breast cancer patient, the cancer being characterized by expression of Her-2/neu, comprising:
a) providing an Ii-Key/MHC class II hybrid construct in a pharmaceutically acceptable carrier, the construct consisting of:
i) the LRMK (SEQ ID NO: 2) amino acid residues of Ii protein; and
ii) an MHC class II epitope-containing segment of Her-2/neu consisting of the sequence GVGSPYVSRLLGICL (SEQ ID NO.: 3) linked at its N-terminus to the residues of element a)i); and
b) stimulating a disease-free breast cancer patient's immune system by vaccination with the hybrid construct of step a) under conditions appropriate for the stimulation of an immune response.
2. The method of claim 1 wherein the immune response comprises an increase in CD4+ T cell production.
3. The method of claim 1 wherein the immune response comprises an increase in a CD4+ T cell response specific to native Her-2/neu peptide.